JP2010515682A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2010515682A5 JP2010515682A5 JP2009544925A JP2009544925A JP2010515682A5 JP 2010515682 A5 JP2010515682 A5 JP 2010515682A5 JP 2009544925 A JP2009544925 A JP 2009544925A JP 2009544925 A JP2009544925 A JP 2009544925A JP 2010515682 A5 JP2010515682 A5 JP 2010515682A5
- Authority
- JP
- Japan
- Prior art keywords
- zileuton
- daily dose
- administered
- pharmaceutical composition
- per day
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US87927307P | 2007-01-05 | 2007-01-05 | |
| PCT/US2008/000101 WO2008085875A2 (en) | 2007-01-05 | 2008-01-04 | R-zileuton for use in conditions associated with increased 5-lipoxygenase and/or leukotriene activity (eg asthma) |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2010515682A JP2010515682A (ja) | 2010-05-13 |
| JP2010515682A5 true JP2010515682A5 (OSRAM) | 2011-03-03 |
Family
ID=39339861
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009544925A Pending JP2010515682A (ja) | 2007-01-05 | 2008-01-04 | 喘息などの５−リポキシゲナーゼ活性上昇および／またはロイコトリエン活性上昇に関連する状態における使用のためのｒ−ジロートン |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20100273868A1 (OSRAM) |
| EP (1) | EP2114399A2 (OSRAM) |
| JP (1) | JP2010515682A (OSRAM) |
| CN (1) | CN101674823A (OSRAM) |
| CA (1) | CA2674492A1 (OSRAM) |
| MX (1) | MX2009007247A (OSRAM) |
| WO (1) | WO2008085875A2 (OSRAM) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2490689A4 (en) * | 2009-10-19 | 2013-03-06 | Panmira Pharmaceuticals Llc | INJECTABLE FORMULATION FOR ADMINISTRATION IN OR NEAR RV |
| CN101829075B (zh) * | 2010-04-27 | 2011-07-20 | 中国人民解放军第三军医大学第一附属医院 | 苦柯胺a和苦柯胺b的用途 |
| EP2563359A1 (en) | 2010-04-30 | 2013-03-06 | Allergan, Inc. | Novel treatment for age related macular degeneration and ocular ischemic disease associated with complement activation by targeting 5-lipoxygenase |
| CN102274213A (zh) * | 2010-06-10 | 2011-12-14 | 北京润德康医药技术有限公司 | 含有r(+)-齐留通的药用组合物 |
| EP2747762B1 (en) * | 2011-08-23 | 2015-07-01 | Cornerstone Therapeutics Inc. | Use of zileuton for the treatment of nasal polyps in cystic fibrosis patients |
| GB201118198D0 (en) * | 2011-10-21 | 2011-12-07 | Jagotec Ag | Improvements in or relating to organic compounds |
| GB201118193D0 (en) * | 2011-10-21 | 2011-12-07 | Jagotec Ag | Improvements in or relating to oranic compounds |
| CN102429872B (zh) * | 2011-11-25 | 2013-07-10 | 舒泰神（北京）生物制药股份有限公司 | 含齐留通的膜控型缓释微丸及其制备方法 |
| TW201615195A (zh) * | 2014-10-24 | 2016-05-01 | 朗齊生物醫學股份有限公司 | 阿那格雷藥物應用於癌症治療 |
| WO2016191520A1 (en) * | 2015-05-26 | 2016-12-01 | Memorial Sloan-Kettering Cancer Center | Ferroptosis and glutaminolysis inhibitors and methods of treatment |
| CA3202852A1 (en) * | 2020-12-01 | 2022-06-09 | Reverspah Llc | Methods and compositions for treating chronic obstructive pulmonary disease, asthma, pneumonia, bronchitis, cystic fibrosis and pulmonary edema, interstitial lung disease, sarcoidosis, idiopathic pulmonary fibrosis, a cute respiratory distress syndrome, and pulmonary arterial hypertension |
| WO2024044654A2 (en) * | 2022-08-23 | 2024-02-29 | University Of Houston System | Parenteral compositions of zileuton and methods of use |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2161777A1 (en) * | 1993-05-10 | 1994-11-24 | Nancy M. Gray | Methods and compositions using optically pure (+)-zileuton |
| EP2409973A1 (en) * | 2006-02-21 | 2012-01-25 | Critical Therapeutics, Inc. | New crystal form and pharmaceutical compositions of (+)-R-zileuton |
-
2008
- 2008-01-04 CA CA002674492A patent/CA2674492A1/en not_active Abandoned
- 2008-01-04 EP EP08712975A patent/EP2114399A2/en not_active Ceased
- 2008-01-04 MX MX2009007247A patent/MX2009007247A/es active IP Right Grant
- 2008-01-04 WO PCT/US2008/000101 patent/WO2008085875A2/en not_active Ceased
- 2008-01-04 JP JP2009544925A patent/JP2010515682A/ja active Pending
- 2008-01-04 US US12/521,965 patent/US20100273868A1/en not_active Abandoned
- 2008-01-04 CN CN200880004777A patent/CN101674823A/zh active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2010515682A5 (OSRAM) | ||
| RU2685730C1 (ru) | Составы соединений азаиндола | |
| RU2700415C1 (ru) | Ингибиторы репликации вирусов гриппа | |
| JP2010248252A5 (OSRAM) | ||
| JP2013537891A5 (OSRAM) | ||
| JP2010518122A5 (OSRAM) | ||
| JP2014506321A5 (OSRAM) | ||
| JP2010515715A5 (OSRAM) | ||
| JP2013536825A5 (OSRAM) | ||
| JP2013519645A5 (OSRAM) | ||
| JP2013526482A5 (OSRAM) | ||
| NO332844B1 (no) | Oral doseringsform inneholdende en PDE4-hemmer som aktivt ingrediens og polyvinylpyrrolidon som eksipiens, anvendelse derav og fremgangsmåte for fremstilling av det samme. | |
| JP2012520866A5 (OSRAM) | ||
| JP2020193206A5 (OSRAM) | ||
| HRP20171511T1 (hr) | Ivabradin-hidroklorid, oblik iv | |
| JP2013509411A5 (OSRAM) | ||
| JP2013518914A5 (OSRAM) | ||
| JP2010500284A5 (OSRAM) | ||
| JP2011157375A5 (OSRAM) | ||
| JP2007500176A5 (OSRAM) | ||
| US9084807B2 (en) | Composition comprising ligustroflavone, rhoifolin and hyperin and its pharmaceutical application | |
| CN105693805A (zh) | 一种胆酸类小檗碱偶合物的制备及医药用途 | |
| CN1988910A (zh) | 含有血小板凝集抑制剂和贝特类化合物的药物组合 | |
| CN101891785A (zh) | 金丝桃苷的提取方法及其制备药物的用途 | |
| CN104095858A (zh) | 闭花木酮Cleistanone的O-(哌啶基)乙基衍生物在制备抗慢性阻塞性肺病药物中的应用 |